- Home
- ZENV vs ADAP Comparison
ZENV vs ADAP Comparison
Compare ZENV & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ADAP
- Stock Information
- Founded
- ZENV 2005
- ADAP 2008
- Country
- ZENV Brazil
- ADAP United Kingdom
- Employees
- ZENV N/A
- ADAP N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- ZENV Technology
- ADAP Health Care
- Exchange
- ZENV Nasdaq
- ADAP Nasdaq
- Market Cap
- ZENV 80.2M
- ADAP 71.6M
- IPO Year
- ZENV 2021
- ADAP 2015
- Fundamental
- Price
- ZENV $1.52
- ADAP $0.27
- Analyst Decision
- ZENV
- ADAP Strong Buy
- Analyst Count
- ZENV 0
- ADAP 5
- Target Price
- ZENV N/A
- ADAP $1.83
- AVG Volume (30 Days)
- ZENV 60.0K
- ADAP 2.0M
- Earning Date
- ZENV 05-06-2025
- ADAP 05-14-2025
- Dividend Yield
- ZENV N/A
- ADAP N/A
- EPS Growth
- ZENV N/A
- ADAP N/A
- EPS
- ZENV N/A
- ADAP N/A
- Revenue
- ZENV $173,594,726.00
- ADAP $178,032,000.00
- Revenue This Year
- ZENV $28.66
- ADAP N/A
- Revenue Next Year
- ZENV $2.98
- ADAP $69.81
- P/E Ratio
- ZENV N/A
- ADAP N/A
- Revenue Growth
- ZENV 23.49
- ADAP 195.34
- 52 Week Low
- ZENV $1.02
- ADAP $0.20
- 52 Week High
- ZENV $3.88
- ADAP $1.48
- Technical
- Relative Strength Index (RSI)
- ZENV 50.89
- ADAP 45.56
- Support Level
- ZENV $1.26
- ADAP $0.23
- Resistance Level
- ZENV $1.51
- ADAP $0.30
- Average True Range (ATR)
- ZENV 0.10
- ADAP 0.03
- MACD
- ZENV 0.02
- ADAP 0.01
- Stochastic Oscillator
- ZENV 100.00
- ADAP 62.67
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.